The US is India’s largest pharmaceutical export market, accounting for $9.47 billion, or 30.4%, of the country’s total pharmaceutical exports of $31.12 billion in FY26, making the proposed tariffs one of the biggest risks facing the sector.
The US is India’s largest pharmaceutical export market, accounting for $9.47 billion, or 30.4%, of the country’s total pharmaceutical exports of $31.12 billion in FY26, making the proposed tariffs one of the biggest risks facing the sector.
<iframe src="https://hindustansphere.com/embed/cluster/7079500172731455883cd72d466f7badc197d895" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Govt, pharma industry lean on trade talks to soften Trump’s drug tariff plan"></iframe>
The US is India’s largest pharmaceutical export market, accounting for $9.47 billion, or 30.4%, of the country’s total pharmaceutical exports of $31.12 billion in FY26, making the proposed tariffs one of the biggest risks facing the sector.
